THE E&M Appoints World-Renowned Scholar Dr. Nam-Joon Cho as New Board Director of Luca AI Cell
THE E&M announced on February 2 that it has appointed Dr. Nam-Joon Cho, founder of Luca AI Cell and a world-renowned expert in biomaterials and infectious disease medicine, as a new board director.
Dr. Nam-Joon Cho is currently serving as Project Leader & Principal Investigator at the "Antiviral Drug Discovery Centers for Pathogens of Pandemic Center" at Stanford University School of Medicine, a project funded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). He is also recognized as a leading authority in the field of infectious disease medicine, having led research on next-generation antiviral therapeutics for emerging infectious diseases.
Dr. Cho is a full professor at the School of Materials Science and Engineering at Nanyang Technological University in Singapore, and has accumulated international research achievements in the fields of biomaterials, cell membrane engineering, and biomedical materials.
To date, he has published more than 300 papers in the world’s most prestigious journals, including Nature. Based on these research accomplishments, he currently serves as an advisor and consultant to the governments of Singapore, Hungary, and South Korea.
Luca AI Cell is a biotech venture company founded in 2020 by Dr. Nam-Joon Cho and former POSCO ICT executive Seunghee Ahn. The company operates a new drug development platform based on universal antiviral peptide therapeutics and proprietary artificial cell membrane technology. In addition to new drug development utilizing lipid nanoparticle (LNP) manufacturing technology, the company is also developing products such as health functional foods and cosmetics.
In particular, Luca AI Cell focuses on core technologies such as next-generation antiviral therapeutic research, artificial cell membrane-based drug delivery technology, and new drug development using lipid nanoparticle (LNP) manufacturing technology. Leveraging these, the company is expanding its business scope beyond pharmaceuticals to include a range of bio-applied products such as health functional foods and cosmetics.
Meanwhile, as the second-largest shareholder of Luca AI Cell, THE E&M has invested approximately 20 billion won since 2020. In 2022, Luca AI Cell also secured an investment of about 5 billion won after being recognized for its technological competitiveness by the Korea Development Bank.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from THE E&M stated, "Luca has been conducting research and development in various fields utilizing its proprietary artificial cell membrane technology," and added, "We expect to see continued achievements in the future."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.